SYGNIS AG

euro adhoc: Sygnis Pharma AG
Fusion/Übernahme/Beteiligung
SYGNIS announces agreement on acquisition of Amnestix Inc., USA by partially using the authorized capital

@@start.t1@@--------------------------------------------------------------------------------   Ad-hoc-Mitteilung übermittelt durch euro adhoc mit dem Ziel einer   europaweiten Verbreitung. Für den Inhalt ist der Emittent verantwortlich. --------------------------------------------------------------------------------@@end@@

Unternehmen

08.06.2008

Heidelberg, June 8, 2008 - Today, after approval of the supervisory board, SYGNIS Pharma AG signed a contract according to which SYGNIS Pharma AG shall acquire all shares of Amnestix Inc., a privately-owned US biopharmaceutical company located at Burlingame, CA. With the acquisition of Amnestix Inc., SYGNIS extends its portfolio of compounds relating to the central nervous system (CNS) and secures IP-rights of compound-candidates for the treatment of CNS-disorders. In addition, SYGNIS gains access to a broad range of CNS projects within the Translational Genomics Research Institute in Phoenix, Arizona, a world-renowned research-institute in the field of neurogenomics. Amnestix was founded by scientists from Translational Genomics Research Institute in 2006 to develop novel therapeutics and molecular diagnostics technologies for improving cognition and memory. The founders of Amnestix Inc. have discovered a series of novel patentable genes and pathways that play a fundamental role in memory performance in humans. Amnestix´ Chief Executive Officer, Dr. Karoly Nikolich, will remain with Amnestix Inc. in this function. SYGNIS will pay approximately EUR4 million in cash and in SYGNIS-shares for all shares of Amnestix Inc. Therefore, the management and supervisory board of SYGNIS Pharma AG resolved today to issue 885.966 new common bearer SYGNIS-shares to the shareholders of Amnestix Inc. for the contribution in kind with the exclusion of the preemptive rights of SYGNIS shareholders. The current company´s capital stock will be increased by approximately 3,2%.

For further information please contact:

Dr. Franz-Werner Haas VP Operations / General Counsel Tel: +49 (0) 6221-454 812 Email: franz-werner.haas@sygnis.de

@@start.t2@@Ende der Mitteilung                                                 euro adhoc
--------------------------------------------------------------------------------@@end@@

ots Originaltext: LION Bioscience AG
Im Internet recherchierbar: http://www.presseportal.ch

Rückfragehinweis:
Dr. Franz-Werner Haas
VP Operations / General Counsel
Tel: +49 (0) 179 212 33 95
Email: franz-werner.haas@sygnis.de

Branche: Biotechnologie
ISIN:      DE0005043509
WKN:        504350
Index:    CDAX
Börsen:  Börse Frankfurt / Regulierter Markt/Prime Standard
              Börse Berlin / Freiverkehr
              Börse Hamburg / Freiverkehr
              Börse Stuttgart / Freiverkehr
              Börse Düsseldorf / Freiverkehr
              Börse Hannover / Freiverkehr
              Börse München / Freiverkehr



Weitere Meldungen: SYGNIS AG

Das könnte Sie auch interessieren: